ALK and neoplasm: In addition, the combination of carboplatin plus paclitaxel with anti-angiogenic drug (Bevacizumab®) and anti-PD-L1 mAb (Atezolizumab®) represents an alternative treatment for patients with non-squamous NSCLC, which just received EMA and FDA approval (FDA approval excludes patients with EGFR or ALK genomic tumor aberrations) (29).